Menu
Back to User profile » Mrs Yuka Tanji
Papers published by Mrs Yuka Tanji:
Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study
Kitamura S, Imai N, Tanji Y, Ozeki A, Komori M
Journal of Pain Research 2023, 16:1725-1738
Published Date: 25 May 2023
Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
Katagiri H, Taketsuna M, Kondo S, Kajimoto K, Aoi E, Tanji Y
Neuropsychiatric Disease and Treatment 2018, 14:1083-1091
Published Date: 23 April 2018
Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
Katagiri H, Taketsuna M, Kondo S, Kajimoto K, Aoi E, Tanji Y
Neuropsychiatric Disease and Treatment 2018, 14:265-272
Published Date: 12 January 2018
Perceptions and impact of bipolar disorder in Japan: results of an Internet survey
Watanabe K, Harada E, Inoue T, Tanji Y, Kikuchi T
Neuropsychiatric Disease and Treatment 2016, 12:2981-2987
Published Date: 21 November 2016
Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M, Conley RR
Neuropsychiatric Disease and Treatment 2012, 8:259-266
Published Date: 18 June 2012
Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
Ye W, Ascher-Svanum H, Flynn JA, Tanji Y, Takahashi M
ClinicoEconomics and Outcomes Research 2012, 4:13-19
Published Date: 13 January 2012
Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M
Patient Preference and Adherence 2011, 5:611-617
Published Date: 14 December 2011